Skip to content
APEIRON Biologics
APEIRON Biologics

APEIRON Biologics

  • Company
    • Corporate Profile
    • APEIRON at a Glance
    • History
  • News
    • Corporate News
    • Scientific Publications
  • Projects
    • Project Overview
    • APN401
    • APN431
    • APN311
    • APN301
    • APN411
    • APN421
    • APN01
  • People
    • Management
    • Supervisory Board
    • Scientific Advisors*
    • Career
  • Investors
  • Meet us
  • Contact
Posted on 17/07/201801/02/2019 by Andreas Neubauer

APEIRON Appoints Peter Llewellyn-Davies as Chief Executive Officer

The former CEO Dr. Hans Loibner will continue to support the Company as senior advisor.

Press release

 Presseaussendung

 

Post navigation

Previous PostPrevious APEIRON, the Medical University of Vienna and the Institute of Molecular Biotechnology Sign Licensing Agreement for a New Checkpoint Inhibitor.
Next PostNext APEIRON Expands Executive Board and Appoints Dr. Anderson Gaweco as Chief Medical and Scientific Officer (CMSO)

Search

Archives

© 2019 APEIRON Biologics AG. All rights reserved.

Legal information | Privacy policy | Cookie policy | Terms of use

Privacy Policy Proudly powered by WordPress
This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Reject Read More
Privacy & Cookies Policy

Non Necessary

This is an non-necessary category.

Save & Accept
WordPress Appliance - Powered by TurnKey Linux